Genetic mechanisms underlying Duchenne muscular dystrophy point to potential treatments
Duchenne muscular dystrophy (DMD) is a rare hereditary disease that is associated with progressive muscle wasting. The ...
FiercePharma4h
Astellas shifts investment focus to later-stage opportunities amid reprioritization
Astellas has invested heavily in novel technologies that are not necessarily the most successful or popular in the industry.
Monthly Prescribing Reference6h
Troculeucel Gets Fast Track Status for Moderate Alzheimer Disease
The Fast Track designation is supported by data from the open-label phase 1 SNK01-MX04 trial, as well as preliminary data from the phase 1 cohort from the phase 1/2a SNK01-AD01 trial.
Biotech Alert: Searches spiking for these stocks today
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...
2 Growth Stocks to Buy Hand Over Fist in February
Not all growth stocks worth buying these days focus on the artificial intelligence field. There are many exciting ones in ...
Analysts Predict Up to ~450% Surge for These 2 ‘Strong Buy’ Penny Stocks
Some of the market’s biggest winners start off as the smallest players. While trillion-dollar tech giants like the ...
Fulcrum: Next Set Of SCD Data Is Crucial For Continued Pipeline Advancement
Fulcrum Therapeutics' promising treatment for Sickle Cell Disease and their strong financial position, despite setbacks.
BridgeBio: Post Attruby Approval, Shares Don't Look Such Good Value - Rating Downgrade
BridgeBio could be an acquisition target, but current financial challenges and competition suggest a "Hold" rating until ...